首页|Centre de Recherche en Cancerologie de Marseille Reports Findings in Machine Learning (Inactive-enriched machine-learning models exploiting patent data improve structure-based virtual screening for PDL1 dimerizers)
Centre de Recherche en Cancerologie de Marseille Reports Findings in Machine Learning (Inactive-enriched machine-learning models exploiting patent data improve structure-based virtual screening for PDL1 dimerizers)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
New research on Machine Learning is the subject of a report. According to news reporting out of Marseille, France, by NewsRx editors, research stated, “Small-molecule Programmable Cell Death Protein 1/Programmable Death-Ligand 1 (PD1/PDL1) inhibition via PDL1 dimerization has the potential to lead to inexpensive drugs with better cancer patient outcomes and milder side effects. However, this therapeutic approach has proven challenging, with only one PDL1 dimerizer reaching early clinical trials so far.” Our news journalists obtained a quote from the research from Centre de Recherche en Cancerologie de Marseille, “There is hence a need for fast and accurate methods to develop alternative PDL1 dimerizers. We aim to show that structure-based virtual screening (SBVS) based on PDL1-specific machine-learning (ML) scoring functions (SFs) is a powerful drug design tool for detecting PD1/PDL1 inhibitors via PDL1 dimerization. By incorporating the latest MLSF advances, we generated and evaluated PDL1-specific MLSFs (classifiers and inactive-enriched regressors) on two demanding test sets. 60 PDL1-specific MLSFs (30 classifiers and 30 regressors) were generated. Our large-scale analysis provides highly predictive PDL1specific MLSFs that benefitted from training with large volumes of docked inactives and enabling inactiveenriched regression.”
NETL
NSTL
